Read our latest news here

Listen to our latest webinar that was recorded on September 14, 2021. Presented by Heather Landau, MD who is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center focused on increasing access to novel, effective therapies in AL amyloidosis and has investigated drugs at all stages of development.  She has conducted multiple investigator-initiated clinical trials exploring novel agents and approaches, including consolidation and maintenance strategies in high-risk patients.  She led the development of MSK’s Outpatient Transplant Service and is studying innovative ways to optimize high-dose therapy and transplant care.

LISTEN HERE

Read our latest newsletter here

Fall 2021 Live Webinar Event

Please join us for our webinar event presented by Dr. Heather Landau.

View Webinar Here

Heather Landau, MD, is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center focused on increasing access to novel, effective therapies in AL amyloidosis and has investigated drugs at all stages of development. She has conducted multiple investigator-initiated clinical trials exploring novel agents and approaches, including consolidation and maintenance strategies in high-risk patients.  She led the development of MSK’s Outpatient Transplant Service and is studying innovative ways to optimize high-dose therapy and transplant care. Pharmacokinetically dosed conditioning has the potential to truly personalize high-dose therapy and Dr. Landau has shown that delivering transplant care at home is safe and improves the quality of life and satisfaction of patients and caregivers. As an active member of the Amyloid Research Consortium (ARC), Dr. Landau has worked with the FDA to identify scientifically rigorous but feasible clinical trials designs and incorporate clinically meaningful endpoints to accelerate drug approval in this disease. Translational research efforts focus on using genomic approaches to understand the biology of pathologic plasma cells in AL amyloidosis, including their sensitivity and resistance to therapies. Partnering with colleagues in pathology and clinical laboratory medicine, Dr. Landau is developing more sensitive methods of detecting and monitoring monoclonal disease using mass spectrometry. As a member of the International Society of Amyloidosis, she has contributed to recently developed clinical guidelines that highlight best practices for hematopoietic cell transplantation. She is a member of the International Myeloma Society and International Kidney Monoclonal Gammopathy Working Group. Dr. Landau’s expertise in the field of amyloidosis leads to frequent invitations to lecture nationally and internationally. She also participates regularly in patient-centered initiatives through the Amyloidosis Research Consortium, Amyloid Foundation, Patient Support Groups and serves as an advisor to Mackenzie’s Mission.

The 3^rd European ATTR Amyloidosis meeting will be hosted 100% virtually on September 6-8, 2021. There will be 2 Channels, one dedicated to doctors and one dedicated to patients, across 3 days delivering a packed and high-quality scientific programme including cutting-edge lectures by international leaders in their field, sessions in collaboration with partnering companies, poster sessions, and much more. It’s the perfect place to keep you updated about ATTR amyloidosis!

Listen to this informative webinar that was recorded on May 26, 2021on the Emerging treatment landscape for Cardiac Amyloidosis. The webinar was hosted by Mathew S. Maurer, MD a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at New York Presbyterian Hospital – Columbia Campus. 

After the presentation, Dr. Maurer answered many interesting questions from patients, physicians and family members.

Please share this link with your family and friends to spread amyloidosis awareness.

LISTEN HERE

Live Webinar Event

Emerging treatment landscape for Cardiac Amyloidosis

Dr. Mathew S. Maurer, MD

Dr. Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation.  He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE). Dr. Maurer is a member of the Advanced Cardiac Care Center at New York-Presbyterian Hospital – Columbia Campus

• When: May 26, 2021
• Time: 3:00 pm EDT

View Webinar Here

WHAT IS A VIRTUAL RUN?

A virtual run is a run that can be run (walked or rolled) from any location you choose. You can run, jog, or walk on the road, on the trail, on the treadmill, at the gym, or on the track. You get to run your own race, at your own pace, and time it yourself. 

Sign Up for the “Run for Your Life” Virtual Run

Registration for the Virtual Run is currently open.

• 5K Run – $25.00
• 10K Run – $35.00

Register Here

Or call the office to register at 248-922-9610.

Once you have signed up for the run, either a 5K or 10K, then decide on the course you want to do, or you can do it on the treadmill. You time yourself. You can even get your friends and/or your kids to run with you too. The run should be completed between May 1, 2021, and July 31, 2021.

Don’t forget to share the run with your friends and family!

Take Photos and Share Your Run with Us

Once you have completed your run, send us some photos to share with kathi@amyloidosis.org.

We would love to hear about your run! Join our Amyloidosis Facebook page and Instagram page. #AFVirtualRun #AFVirtualRun2021 #VirtualRun2021 #RunforyourLife2021

CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. announced today that the European Commission (EC) has granted orphan drug designation to NTLA-2001. This investigational medicinal product is being developed as a treatment for transthyretin amyloidosis (ATTR).

Read full article here.

By BIOENGINEER – March 16, 2021

Memphis, Tenn. (March 16, 2021) – The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center’s Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled “Developing a Theranostic Immunotherapy for Systemic Amyloidosis.”

Read the full article here.